Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Arctic Bioscience AS ( (DE:9TD) ) is now available.
Arctic Bioscience has secured new long-term financing backed in part by guarantees from companies closely related to its board members. Ronja Capital AS, linked to board member Tore Tønseth, has guaranteed NOK 10 million, while Vartdal Holding AS and Brødrene Vartdal AS, both linked to board member Jan Endre Vartdal, have each guaranteed NOK 1.5 million.
These insider-related guarantees signal tangible support from key stakeholders for the company’s financing package and ongoing strategy. The disclosure underscores regulatory compliance under European market abuse and Norwegian securities rules, and may bolster market confidence in Arctic Bioscience’s capital structure and ability to advance its pharmaceutical and nutraceutical initiatives.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements based on unique bioactive marine raw materials. Its pipeline includes HRO350, an oral drug candidate for mild to moderate psoriasis, while its ROMEGA-branded marine-derived dietary supplements are sold globally as bulk ingredients and finished products.
Average Trading Volume: 17,652
Current Market Cap: NOK88.96M
See more insights into 9TD stock on TipRanks’ Stock Analysis page.